Recent Transactions

24-Mar-06
$21.2 billion
Germany flag
Target: 

Schering AG

Germany flag
Acquiror: 
Bayer AG

Advised Bayer on its public offer for Schering, an international pharmaceuticals group based in Berlin, Germany

26-Mar-07
$1.0 billion
Netherlands flag
Target: 

Wolters Kluwer Education

United Kingdom flag
Acquiror: 
Bridgepoint Capital Limited

Advised Bridgepoint Capital Limited on its acquisition of Wolters Kluwer Education, the pan-European educational publishing division of quoted Dutch-based information services and publishing company Wolters Kluwer NV

02-Jan-08
$NA
Germany flag
Target: 

E. Brost & J. Funke GmbH & Co. KG (BFK KG) and its 25% stake in Otto Group

Germany flag
Acquiror: 
Otto AG für Beteiligungen (investment vehicle of Otto family)

Advised the shareholders of BFK KG, comprising the families who also own German publisher WAZ Media Group, on the sale of their 25% holding in German retailing and services group Otto to the Otto family, which thereby regained full ownership of the business

22-Jan-08
$3.4 billion
United States flag
Target: 

Ventana Medical Systems, Inc.

Switzerland flag
Acquiror: 
Roche Holding Ltd.

Advised Roche Holding Ltd., a world-leading provider of healthcare pharmaceuticals and diagnostics, on its acquisition of Ventana Medical Systems, Inc., a US based provider of histopathology diagnostic equipment

12-Mar-09
$46.9 billion
United States flag
Target: 

Genentech, Inc.

Switzerland flag
Acquiror: 
Roche Holding Ltd.

Advised Roche Holding Ltd., a world-leading provider of healthcare pharmaceuticals and diagnostics, on its acquisition of the outstanding publicly held interest in Genentech, Inc., a leading biotechnology company

09-Nov-09
$327 million
United States flag
Target: 

Enzon Pharmaceuticals, Inc.

Italy flag
Acquiror: 
Sigma-Tau Pharmaceuticals

Advised Enzon Pharmaceuticals, Inc., a biopharmaceutical company on the sale of its specialty pharmaceutical business to Sigma-Tau, an Italian pharmaceutical company

04-Dec-09
$NA
Germany flag
Target: 

Verivox Holding Limited

United Kingdom flag
Acquiror: 
Oakley Capital Private Equity LP

Advised the shareholders of Verivox Holdings Limited, comprising Independent News & Media plc and the founders and joint CEOs of Verivox, on the sale of 51% in Verivox, Germany’s leading price comparison website for energy and telecommunications services, to Oakley Capital Private Equity

01-Jul-10
$NA
Australia flag
Target: 

Media Monitors

Australia flag
Acquiror: 
Quadrant Private Equity

Advised Media Monitors, the leading media intelligence company in Asia-Pacific, on its sale to Quadrant Private Equity

29-Jul-10
$328 million
Australia flag
Target: 

Mitchell Communication Group Limited

United Kingdom flag
Acquiror: 
Aegis Group plc

Advised Aegis Group plc on its acquisition of Mitchell Communication Group Limited, Australia’s leading independent media buyer

26-Nov-10
$118 million
Australia flag
Target: 

Healthcare Australia

United Kingdom flag
Acquiror: 
Healthcare Locums

Advised CHAMP Private Equity on the sale of Healthcare Australia, a leading provider of nursing agency staff to public and private health institutions in Australia, to Healthcare Locums, a healthcare recruitment agency based in the UK

15-Dec-10
$12.9 billion
U.S.A., Swiss flags
Target: 

Alcon, Inc.

Switzerland flag
Acquiror: 
Novartis AG

Advised the Independent Director Committee of Alcon, Inc., an ophthalmic pharmaceutical company, on the sale of Alcon’s outstanding publicly held interest to Novartis AG, a global pharmaceutical company

27-Jul-11
$850 million
United Kingdom flag
Target: 

The Synovate Group

France flag
Acquiror: 
Ipsos S.A.

Advised Aegis Group plc on the sale of The Synovate Group, a leading global provider of custom market research, to Ipsos S.A.

21-Nov-11
$689 million
Australia flag
Target: 

iNova Pharmaceuticals

United States flag
Acquiror: 
Valeant Pharmaceuticals

Advised Archer Capital and Ironbridge Capital on the sale of iNova Pharmaceuticals, a leading pharmaceuticals company that sells and distributes a range of prescription and over-the-counter products in Australia, New Zealand, Asia and Southern Africa, to Valeant Pharmaceuticals

12-Jul-12
$5.0 billion
United Kingdom flag
Target: 

Aegis Group plc

Japan flag
Acquiror: 
Dentsu Inc.

Advised Aegis Group plc, a leading global media and digital communications agency, on its sale to Dentsu Inc., the leading advertising group in Asia

21-Aug-12
$1.1 billion
Australia flag
Target: 

Broadcast Rights for the National Rugby League

Australia flag
Acquiror: 
Nine Network / Fox Sports

Advised the Australian Rugby League Commission on the sale of the Australian television broadcasting rights for the National Rugby League to Nine, a leading Free to Air broadcaster and Fox Sports, Australia’s largest pay TV broadcaster (partially owned by News Limited)

02-Sep-12
$285 million
U.K., Australia flags
Target: 

DMG Radio Australia, a subsidiary of Daily Mail and Guardian Trust Plc

Australia flag
Acquiror: 
Illyria Pty

Advised Daily Mail and Guardian Trust plc (DMGT), on the sale of its remaining 50% interest in its Radio business in Australia to Illyria Pty, a private investment company of Lachlan Murdoch. The Radio operations comprise two national music networks in Australia

01-Nov-12
$180 million
New Zealand flag
Target: 

SKY Network Television Limited

Advised Todd Corporation, a major New Zealand family office, on the divestment of its 11.1% holding in SKY Network Television Limited, New Zealand’s leading provider of pay television services

15-Jan-13
$NA
Australia flag
Target: 

Broadcast Rights for V8 Supercars

Australia flag
Acquiror: 
Seven Network

Advised Archer Capital, a leading Australian private equity firm, and its portfolio company V8 Supercars Australia, on the sale of the Australian FTA television broadcasting rights for V8 Supercars to Seven, a leading Free to Air broadcaster in Australia

20-May-13
$8.5 billion
Ireland flag
Target: 

Warner Chilcott, plc

United States flag
Acquiror: 
Actavis, Inc.

Advised Actavis, Inc., a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, branded and biosimilar products on its acquisition of Warner Chilcott plc

31-May-13
$500 million
Australia flag
Target: 

iSelect (30% shareholding)

Australia flag
Acquiror: 
Ninemsn (T/A Mi9)

Advised Mi9, a joint venture between Microsoft and Nine Entertainment Co, and one of Australia’s leading digital media companies, on the sale of its 30% holding in iSelect, a leading Australian online-driven comparison service, as part of the Initial Public Offering of iSelect

18-Dec-13
$NA
Australia flag
Target: 

Global Television

United States flag
Acquiror: 
NEP Group Inc.

Advised Catalyst Investment Managers on the sale of its portfolio company Global Television, Australia’s largest provider of outsourced broadcasting and video production services, to NEP Inc., a leading provider of total broadcast solutions in the US, UK and Brazil. NEP is majority-owned by private funds managed by Crestview Partners

18-Dec-13
$141 million
Australia flag
Target: 

Open Colleges Australia Pty Ltd

United States flag
Acquiror: 
Apollo Education Group, Inc.

Advised Open Colleges, Australia’s leading privately owned online provider in the high-growth vocational education and training sector, on the sale of a 70% stake (plus exit arrangements for the balance) to Apollo Education Group, Inc., one of North America’s largest private education providers

18-Feb-14
$25.1 billion
United States flag
Target: 

Forest Laboratories Inc.

Ireland flag
Acquiror: 
Actavis plc

Advised Actavis plc, a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products on its acquisition of Forest Laboratories Inc.

08-Apr-14
$NA
United States flag
Target: 

ARTnews

Russia flag
Acquiror: 
Skate Capital Corp.

Advised ARTnews, the world's oldest and most widely circulated art magazine, on its sale to Skate Capital Corp., a private art and media industry investment vehicle

28-Jul-14
$90 million
Australia flag
Target: 

Clinuvel Pharmaceuticals Limited

United States flag
Acquiror: 
Retrophin, Inc.

Advised Clinuvel, a biopharmaceutical company focused on developing drugs for the treatment of a range of severe skin disorders, in response to an unsolicited proposal to acquire the business from Retrophin, a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases

Pages

show all